You are here

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

Last updated on March 11, 2019

FOR MORE INFORMATION
Study Location
Phoenix, Arizona, 85013 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of probable AD according to the NINCDS-ADRDA criteria.

- Able to give informed consent. Patient` s caregiver must consent to participate in the
study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Use of medications for cognitive enhancement within 3 months of baseline.

- Significant neurologic disease other than AD that may affect cognition.

NCT00151398
Pfizer
Completed
Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now